NCT07892443Not yet recruiting
Type 2 Inflammation in Adults With Cystic Fibrosis
Importance of Type 2 Inflammation in Adults With Cystic Fibrosis and Recurrent Pulmonary Exacerbations
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
The goal of this observational study is to better understand why some adults with cystic fibrosis (CF) continue to have repeated pulmonary exacerbations, or episodes of worsening respiratory symptoms, despite treatment with highly effective CFTR modulator therapy. The study will focus on whether a type of inflammation called type 2 (T2) inflammation may contribute to these pulmonary exacerbations. The main questions this study aims to answer are: Are signs of T2 inflammation more common in adults with CF who have frequent pulmonary exacerbations? Are there differences in inflammation in the nose and airways between people who have frequent pulmonary exacerbations and those who do not? How do immune cells and inflammation change during a pulmonary exacerbation? Participants will: Allow researchers to collect information about their CF and pulmonary exacerbations from their medical records. Complete questionnaires about respiratory and sinus symptoms and quality of life. Provide research blood samples, samples from inside the nose, and exhaled breath condensate. Be followed for up to approximately 3 years, with additional research samples collected during qualifying pulmonary exacerbations when feasible. Participants will continue to receive their usual CF medical care. No experimental medications or treatments will be given as part of this study.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 22 Sept 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 31 May 2031
- Lead sponsor
- University of Virginia
- Diseases
- Cystic fibrosis
- NCT number
- NCT07892443
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Nov 2026 to the primary completion date, 31 May 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hospitalization for a pulmonary exacerbation within the 4 weeks before enrollment
- New systemic antibiotic treatment for respiratory symptoms within the 4 weeks before enrollment
- Systemic corticosteroid treatment for respiratory symptoms within the 4 weeks before enrollment
Other illness
- Any condition that, in the opinion of the investigator, would make participation in the study unsafe or interfere with completion of study procedures
Other
- Active pulmonary exacerbation at the time of enrollment
- Pregnancy at the time of enrollment
Who the study is looking for
- Age 18 years or older
- Diagnosis of cystic fibrosis
- Receiving highly effective CFTR modulator therapy (HEMT) for at least 6 weeks before enrollment
- Clinically stable at the time of enrollment
- Receives cystic fibrosis care through the University of Virginia Adult Cystic Fibrosis Program
- Able and willing to provide informed consent and participate in study procedures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.